The US Food and Drug Administration (FDA) has released new draft guidance to enhance racial, ethnic, and other forms of diversity in clinical trials conducted by drugmakers and medical device manufacturers. The recommendations offer a structured approach for companies and researchers to set and achieve enrolment goals segmented by age, ethnicity, sex, and race. The initiative seeks to address the…